Technology Networks

The Changing Landscape of Companion Diagnostics

Dr. Madhuri Hegde explores the changing landscape of CDx, the technologies accelerating its progress, and the challenges ...
FiercePharma

Opportunities & Challenges of Digital Pathology Adoption in CDx Development

In the dynamic world of life sciences, digital pathology stands out as a beacon of innovation, promising transformative changes in how pathologists engage, evaluate, and collaborate. In this episode, ...

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...
The American Journal of Managed Care

FDA Approves FoundationOne Liquid CDx as a Diagnostic Tool for BRCA-Mutated mCRPC

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...
Healio

FDA grants premarket approval to Idylla CDx MSI test for patients with colorectal cancer

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for ...
Pharmabiz

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...